Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases
April 15, 2024 07:00 ET
|
Walden Biosciences, Inc.
Proprietary Human anti-suPAR Monoclonal Antibody Demonstrated Safety and Reduction of Circulating Free suPAR, a Cause of Kidney Disease Plans to Initiate Phase 2 Basket Study in Glomerular Kidney...
Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases
June 05, 2023 07:48 ET
|
Walden Biosciences, Inc.
Trial to Evaluate Proprietary Human anti-suPAR Monoclonal Antibody for Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers Expects to Complete Enrollment by Year End 2023 CAMBRIDGE,...
Walden Biosciences Announces Participation in Citi’s 17th Annual BioPharma Conference
August 31, 2022 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Walden Biosciences Announces Presentation at Canaccord Genuity 42nd Annual Growth Conference
August 04, 2022 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...